Recurrent UTI in Women: Why It Keeps Coming Back and What Stops It

A urinary tract infection (UTI) that happens once is unpleasant. A UTI that happens three times in a year, or twice in six months, is something else entirely. It disrupts work, relationships and sleep. It creates a cycle of antibiotics that feels like the only option available, and yet the infections keep returning. For many women, this is not a temporary problem, but a pattern that has been going on for years.

A recurrent UTI is defined clinically as two or more infections within six months, or three or more within twelve months.¹ It affects a significant proportion of women. In fact, up to half of all women will have at least one UTI in their lifetime, and of those, almost half will experience a recurrence within six to twelve months.² Understanding why this happens, what sustains the cycle, and which treatments can reduce the risk beyond repeated antibiotic prescriptions is the starting point for breaking it.

Why Are Women More Susceptible To UTIs?

The anatomical difference that makes women considerably more vulnerable to UTIs than men is the length of the urethra. In women, the urethra is approximately four centimetres long, compared with around twenty centimetres in men, meaning bacteria from the perineal area have a much shorter distance to travel to reach the bladder.³

Escherichia coli, the bacterium responsible for the majority of UTIs, is a natural inhabitant of the gut and perineal area, and its proximity to the urethral opening creates a persistent risk of ascending infection.^1,2 Sexual activity is one of the strongest independent risk factors for UTIs in premenopausal women, increasing the mechanical displacement of bacteria toward the urethra.³ Spermicide use and certain contraceptive methods alter the vaginal microbiome in ways that further increase susceptibility.³ Genetic factors also play a role, influencing how readily bacteria can adhere to the cells lining the urinary tract and how strongly the immune system responds to early infection.

What Relationship Do UTIs Have With Oestrogen And Menopause?

In postmenopausal women, recurrent UTIs become substantially more common, and the mechanism is predominantly hormonal, related to falling oestrogen levels.⁴ Oestrogen plays a central role in maintaining the health of the vaginal and urethral tissues. It promotes the production of glycogen that feeds protective lactobacillus bacteria, and helps maintain an acidic vaginal environment that resists colonisation by harmful bacteria.⁵

When oestrogen levels fall during and after the menopause, this protective environment breaks down. The vaginal and urethral tissues thin and become more susceptible to irritation and infection.5 Their absence allows more diverse and potentially pathogenic bacteria to colonise the vaginal and urethral environment, with the protective Lactobacillus species declining, creating conditions in which ascending infection becomes more likely with each passing month.⁵

Research has shown that the urinary microbiome, the community of micro-organisms that inhabit the bladder, has a different composition in women with recurrent UTIs compared with those who do not experience recurrence, and that oestrogen deficiency is one of the drivers of this shift.⁶

Why Are Antibiotics Not Always Enough?

Antibiotics treat a urinary tract infection when it occurs. They do not address all of the underlying factors that make infection likely to happen again. For women with recurrent urinary tract infection, long-term antibiotic prophylaxis, taking a low-dose antibiotic daily (when other measures have failed) or a single dose after intercourse to suppress infection, is the standard approach offered in most NHS settings.

Long-term antibiotics can be effective during the period of use, but the evidence for sustained benefit once antibiotics are stopped is limited, and the risk of driving antimicrobial resistance is real and clinically significant.¹ A review published in the British Journal of General Practice found that 6% of women registered in primary care practices (2010-2020) met the criteria for recurrent UTI, with the proportion rising sharply in women aged 58 to 67.⁷

The research also revealed that antibiotic prophylaxis was the predominant management strategy despite the limitations this carries at a population level.⁷ Yet as rates of antibiotic resistance in urinary pathogens increase, the effectiveness of standard prophylaxis is likely to diminish further, making non-antibiotic prevention strategies increasingly important both for patients and public health.

How Does Topical Oestrogen Act As A Preventive Treatment?

For peri- and postmenopausal women with recurrent UTIs, topical vaginal oestrogen is an evidence-based preventive treatment that works by addressing one of the underlying causes of increased susceptibility, the hormonal cause, rather than the infection itself. Applied locally as a cream, pessary, tablet or ring, vaginal oestrogen restores the normal thickness and resilience of the urethral and vaginal tissues, promotes the re-establishment of a protective lactobacillus-dominant microbiome, and reduces the frequency of recurrent UTIs in postmenopausal women.⁴

It is distinct from systemic hormone replacement therapy (HRT) and carries a different risk profile, making it appropriate for a wider range of women, including those with certain conditions that preclude systemic oestrogen. Only a minimal amount is absorbed into the bloodstream compared with systemic HRT, and serious side effects are considered very rare. However, suitability still needs to be assessed individually. NICE guidelines recommend that topical oestrogen should be offered to peri- and postmenopausal women with recurrent UTIs as a non-antibiotic preventive option, and it is significantly underused relative to the scale of the problem it is designed to address.⁸

What Uromune Is And Why Does It Matter?

Uromune, also known by its clinical name MV140, is a bacterial sublingual vaccine developed specifically for the prevention of recurrent UTIs. It is administered as a daily spray under the tongue for three months, and it works by exposing the immune system to inactivated forms of the four bacteria most commonly responsible for urinary tract infections: Escherichia coli, Klebsiella pneumoniae, Proteus vulgaris and Enterococcus faecalis.⁹

This stimulates both local immunity and broader immune responses that make the urinary tract less vulnerable to repeated bacterial colonisation.⁹ The clinical evidence for Uromune is robust. A phase III randomised, double-blind, placebo-controlled trial published in NEJM Evidence in 2022 found that women receiving MV140 had a median of zero UTIs in the nine months following treatment, compared with a median of three in the placebo group.

Between 56% and 58% of women receiving MV140 were completely infection-free during the follow-up period, compared with 25% in the placebo group.¹⁰ Long-term follow-up data from UK patients, including work led by the team that conducted the first UK experience of Uromune, suggest that clinical benefits may be sustained over multiple years, with some patients maintaining meaningful protection well beyond the initial treatment period.¹¹

Access to Uromune currently requires referral to a specialist urology service, and for women who have been cycling antibiotics for months or years without resolution, it represents a meaningfully different approach.

What Does Assessment Involve?

A clinical assessment for recurrent UTIs should establish:

• The pattern and frequency of infections
• The micro-organisms responsible and their antibiotic sensitivity profiles
• Any contributing anatomical or physiological factors
• Whether hormonal status is a relevant contributor.
• Whether there are recognisable triggers, such as sexual intercourse
• Whether another condition could be causing or contributing to the symptoms.

Urine cultures taken during symptomatic episodes are more informative than dipstick tests alone, and a clear microbiological picture is useful before deciding on the most appropriate preventive strategy. Where practical, the sample should be collected before antibiotics are started.

For peri- and postmenopausal women, assessment should include consideration of vaginal oestrogen and, where recurrence persists despite standard measures, discussion of immunoprophylaxis with Uromune as an alternative to continued antibiotic dependence.

References